ICIon Codreanu

Ion Codreanu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ion Codreanu has a total of 172 co-authors. Here are the top co-authors by number of shared publications:

  • Constantin A. Dasanu

    Christus Health

    18 shared publications
  • Hongming Zhuang

    14 shared publications
  • Kieran Clarke

    University of Oxford

    11 shared publications
  • Jigang Yang

    From the *Department of Nuclear Medicine, Beijing Friendship Hospital of Capital Medical University, Beijing, People's Republic of China; †Department of Radiology, The Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; ‡Department of Radiology, Medpark International Hospital, State University of Medicine and Pharmacy Nicolae Testemitanu, Chi[Latin Small Letter s with comma below]inău, Moldova

    10 shared publications
  • Sabah Servaes

    10 shared publications
  • Hongming Zhuang

    Department of Radiology, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

    9 shared publications

Latest Publications

  • Open Access

    The Role of Dynamic Contrast Enhanced Magnetic Resonance Imaging in Evaluating Prostate Adenocarcinoma: A Partially‐Blinded Retrospective Study of a Prostatectomy Patient Cohort With Whole Gland Histopathology Correlation and Application of PI‐RADS or TNM Staging

    by Sajeev Sridhar, Zeyad Abouelfetouh, Ion Codreanu, Nakul Gupta, Shu Zhang, Eleni Efstathiou, Daniel K. Karolyi, Steven S. Shen, Peter S. LaViolette, Brian Miles, et al.

    Background: Dynamic contrast‐enhanced (DCE) magnetic resonance imaging (MRI) in the current Prostate Imaging‐Reporting and Data System version 2.1 (PI‐RADS v2.1) is considered optional, with primary scoring based on T2‐weighted imaging (T2WI) and diffusion weighted imaging (DWI). Our study is designed to assess the relative contribution of DCE MRI in a patient‐cohort with whole mount prostate histopathology and spatially‐mapped prostate adenocarcinoma (PCa) for reference.Methods: We performed a partially‐blinded retrospective review of 47 prostatectomy patients with recent multi‐parametric MRI (mpMRI). Scans included T2WI, DWI with apparent diffusion coefficient (ADC) mapping, and DCE imaging. Lesion conspicuity was scored on a 10‐point scale with ≥ 6 considered “positive,” and image quality was assessed on a 4‐point scale for each sequence. The diagnostic contribution of DCE images was evaluated on a 4‐point scale. The mpMRI studies were assigned PI‐RADS scores and tumor, node, metastasis (TNM) T‐stage with blinded comparison to spatially‐mapped whole‐mount pathology. Results were compared to the prospective clinical reports, which used standardized PI‐RADS templates that emphasize T2WI, DWI and ADC.Results: Per lesion sensitivity for PCa was 93.5%, 82.6%, 63.0%, and 58.7% on T2WI, DCE, ADC and DWI, respectively. Mean lesion conspicuity was 8.5, 7.9, 6.2, and 6.1, on T2W, DCE, ADC and DWI, respectively. The higher values on T2WI and DCE imaging were not significantly different from each other but were both significantly different from DWI and ADC (p < 0.001). DCE scans were determined to have a marked diagnostic contribution in 83% of patients, with the most common diagnostic yield being detection of contralateral peripheral zone tumor or delineating presence/absence of extra‐prostatic extension (EPE), contributing to more accurate PCa staging by PI‐RADS or TNM, as compared to histopathology.Conclusion: We demonstrate that DCE may contribute to lesion detection and local staging as compared to T2WI plus DWI‐ADC alone and that lesion conspicuity using DCE is markedly improved as compared to DWI‐ADC. These findings support modification of PI‐RADS v2.1 to include use of DCE acquisitions and that a TNM staging is feasible on mpMRI as compared to surgical pathology.


  • The role of digital tomosynthesis in laryngeal cancer: comparison with radiography and computed tomography

    by Dorina Jovmir-Popa, Ion Codreanu, Igor Gavrilasenco, Marina Harea

    Digital tomosynthesis is a relatively new imaging modality that is already used in the diagnosis of breast cancer and has shown promising results in evaluating patients with pulmonary, osteoarticular, and other pathologies. However, up to date, there are no published studies related to the usefulness of digital tomosynthesis in the evaluation of patients with laryngeal cancer. The purpose of this study was to evaluate the clinical role of digital tomosynthesis in the diagnosis of laryngeal cancer and compare the imaging results with those obtained by digital radiography and computed tomography. Material and methods. The study was carried out between 2015 and 2019 at the Institute of Oncology in the Republic of Moldova and included 253 consecutive patients with laryngeal cancer referred to the Institute of Oncology during this period. All patients underwent digital radiography and digital tomosynthesis investigations. In 41 patients who provided written informed consent, computed tomography was performed. The results of all imaging investigations were compared. Results. The statistical analysis revealed a high degree of agreement and a strong linear correlation between the data obtained with digital tomosynthesis and computed tomography, as well as concordance correlation coefficients for different parameters between 0.63 and 1.0 (mean value = 0.82±0.11). For comparison, the concordance correlation coefficients for the same parameters obtained for digital radiography versus computed tomography ranged between 0.08 and 0.93 (mean value = 0.43±0.25). An updated imaging algorithm that includes digital tomosynthesis has also been proposed for investigating patients with suspected laryngeal cancer. Conclusions. The study demonstrated the usefulness of digital tomosynthesis for the evaluation of patients with laryngeal cancer. When compared to computed tomography, which is considered the gold standard, digital tomosynthesis revealed a much higher performance compared to digital radiography. Considering the availability of low-dose protocols for digital tomosynthesis, the modality might also be helpful for laryngeal cancer screening in a high-risk population. However, new studies are also required to confirm our findings and define the place of digital tomosynthesis in the imaging algorithm for patients with laryngeal cancer.

  • Audit of radiology reports of patients with neoplasms performed on computed tomography

    by Natalia Staver, Ion Codreanu

    Background: Evaluation of the peculiarities of radiology reports of patients with neoplasms of the abdomen and pelvis to optimize clinical imaging management. Material and methods: The study included 104 patients, divided into two groups, experimental group (L2) and control group (L1), repeatedly investigated by computed tomography in 2009-2019, a total of 440 examinations, of which 120 prospective examinations and 320 retrospective examinations, aged between 25 and 85 years, with primary tumors of the abdomen and pelvis. Results: Four specific descriptive criteria were analyzed from radiology reports and were obtained the following results: specification of the scanning protocols in radiology reports (0% for L1 and 95.3% for L2), specifying the reason for the examination in radiology reports (100% for L1 and 26.0% for L2), use of international terminology in radiology reports (0% for L1 and 74% for L2), patient follow-up in radiology reports (88.5% for L1 and 59.8 % for L2). Conclusions: Following the SWOT analysis of the radiology reports, has been developed a standardized model for describing CT images of patients with oncological pathologies of the abdomen and pelvis. The decision-making process was built on Strengths, eliminating Weaknesses, exploiting Opportunities and removing Threats.

  • Severe left atrial enlargement due to carfilzomib use in multiple myeloma

    by Constantin A Dasanu, Steven C Plaxe, Iliana M Popescu, Varun Gupta, Eric Sontz, Ion Codreanu

    Several cardiovascular effects have been attributed to carfilzomib in the recent literature. These side effects must be recognized promptly by treating physicians and pharmacists. Special attention is required in patients with pre-existing cardiac conditions, liver function abnormalities and/or advanced age. This is the first report of a severe left atrial enlargement due to carfilzomib use in the setting of multiple myeloma. This condition improved dramatically seven months after cessation of carfilzomib. The authors discuss further various cardiac and vascular abnormalities linked with carfilzomib in the medical literature. Prompt withdrawal of this agent is essential in these cases as it may prevent dismal outcomes.


  • Open Access

    Merkel cell carcinoma: long-term follow-up of a single institution series and clinical outcomes by immunological status

    by Constantin A Dasanu, Michael Del Rosario, Ion Codreanu, Yani Lu, Stephanie Farrell, David M Hyams, Steven C Plaxe

    Merkel cell carcinoma (MCC) usually arises in sun-exposed areas of older patients and might be more aggressive in the immunocompromised. We performed a retrospective chart review of 40 consecutive MCC patients treated at our institution between the years 2006-2017. Clinical and epidemiologic data were utilized and therapy and survival were analyzed. Compared to Surveillance, Epidemiology, and End Results (SEER) data, our population was entirely Caucasian (100% versus 95%; P=0.11) and male predominant (75% versus 63%; P=0.11). The median age was 76. The patients more often had Tumor-Node-Metastasis (TNM) stage I disease (50% versus 39%; P=0.00003) and a primary tumor size<2cm (57.5% versus 34%; P<0.01). They received more frequently lymph node dissection (70% versus 63%, P=0.002) compared with the SEER findings. We identified a subset of immunocompromised patients (n=10) who presented with more stage III disease (40% versus 33%; P=0.021). Time to death averaged 290.1 days in this subset versus 618.2 days (P<0.001) in immunocompetent patients and their likelihood of death was 5 times higher. As clinical outcomes in MCC patients vary by immunological status, a multidisciplinary tumor-board approach may better optimize individual patient management.


  • Bevacizumab in refractory higher-grade and atypical meningioma: the current state of affairs

    by Constantin A. Dasanu, Juliana Alvarez-Argote, Farhad M. Limonadi, Ion Codreanu

    Introduction: Historically, systemic agents had shown limited efficacy in meningioma, at the expense of significant pharmacologic and/or financial toxicity. As meningiomas are highly vascularized, they might derive benefit from antiangiogenic therapy. Areas covered: This review summarizes the literature regarding bevacizumab pharmacology, safety and efficacy in patients with refractory meningioma. We have searched PubMed/Medline database for pertinent articles published from inception to 1 September 2018. Expert commentary: Results of two prospective phase II trials, supported by several retrospective cohorts, suggest a clinical benefit for the vascular endothelial growth factor inhibitor bevacizumab in meningiomas refractory to surgery and radiation therapy. This agent has a tolerable toxicity profile and seems more effective in higher-grade histologies and atypical meningioma, although responses in low-grade meningiomas have also been documented. Our conclusions are restricted due to a small size and lack of control in the prospective trials as well as the retrospective design of other studies. Further study of bevacizumab in refractory higher-grade meningiomas seems warranted.


  • Systemic therapy for relapsed/refractory meningioma: Is there potential for antiangiogenic agents?

    by Constantin A Dasanu, Yazeed Samara, Ion Codreanu, Farhad M Limonadi, Omid Hamid, Juliana Alvarez-Argote

    Effective therapies for relapsed/refractory meningioma after surgery and radiation therapy represent an unmet need. Most meningiomas are highly vascularized tumors and, therefore, potentially amenable to antiangiogenic therapy. Herein, we review comprehensively the scientific literature on systemic therapy options for relapsed, persistent or metastatic meningioma, not amenable to local therapy. Also, this review offers insights into the function of vascular endothelial growth factor/receptor pathway both in health and disease. Further, we address the current status of the preclinical and clinical studies targeting vascular endothelial growth factor/receptor signaling in meningioma. Most relevant publications were identified through searching the PubMed/Medline database for articles published from inception to 1 February 2018. Vascular endothelial growth factor pathway activation might represent the primary driver of angiogenesis in meningioma. Positive findings of two prospective phase II trials, supported by the results of several retrospective cohorts, suggest a clinical benefit for the vascular endothelial growth factor inhibitor bevacizumab in refractory meningioma. Bevacizumab causes both peritumoral brain edema reduction and true meningioma shrinkage. Patients with WHO grades II–III meningioma appear to benefit more than patients with grade I disease. Similarly, responses have been documented with certain oral targeted anti-vascular endothelial growth factor/receptor agents. Further exploration of the role of vascular endothelial growth factor/receptor inhibitors in refractory meningioma seems warranted.


  • Inferior outcomes in immunocompromised Merkel cell carcinoma patients: Can they be overcome by the use of PD1/PDL1 inhibitors?

    by Constantin A Dasanu, Michael Del Rosario, Ion Codreanu, David M Hyams, Steven C Plaxe

    Cases of Merkel cell carcinoma have become increasingly more common in the last two decades, and its incidence has been predicted to climb further. Immunosenescence might explain in part the higher Merkel cell carcinoma prevalence in seniors aged 70 and older. This cancer might also be more aggressive in immunocompromised patients. In a subset of immunocompromised Merkel cell carcinoma patients, we identified significant lymphopenia and a more advanced disease stage compared with their immunocompetent counterparts. Time to death in this cohort was much shorter than in immunocompetent subjects, and their likelihood of death from Merkel cell carcinoma was five times higher. Avelumab approval in 2017 represents an important step forward in the therapy of Merkel cell carcinoma. Hopefully, PD1/PDL1 inhibitors will improve survival in immunocompromised Merkel cell carcinoma hosts, traditionally linked with inferior clinical outcomes.


  • Organized Breast Seroma Mimicking Local Tumor Recurrence

    by Natalia Rotaru, Janna Punga, Maxim Crivceanschii, Ion Codreanu


  • Local Fibrinolysis in Spontaneous Supratentorial Hematomas: Comparison with Surgical and Medical Treatment

    by Eugeniu Condrea, Valeriu Timirgaz, Stanislav Groppa, Ion Codreanu, Natalia Rotaru

    Objective: To evaluate the effectiveness of minimally invasive craniopuncture with local fibrinolysis in the management of supratentorial spontaneous intracerebral hemorrhage (SICH). Methods: The study included 218 consecutive patients with supratentorial SICH who were assigned to one of three groups: treated with minimally invasive craniopuncture with local fibrinolysis, treated with craniotomy or other minimally invasive techniques without local fibrinolysis, or receiving conservative management alone. Results: Minimally invasive craniopuncture with local fibrinolysis was associated with a lower rate of assisted ventilation, a shorter period of in-hospital stay, a more frequent initiation of early rehabilitation, and a lower mortality rate at all periods of assessment. The overall mortality at 12 months was 19.4% (vs. 50.0 and 33.3% in the two other therapy groups). Lobar (subcortical and cortical) SICHs treated with local fibrinolysis had an overall mortality of 4.8% (vs. 43.5 and 41.7% in the two other therapy groups). On the other hand, SICHs having mixed (basal ganglia and lobar) locations treated with medical therapy alone had an overall mortality of 28.6%, while associated surgery with or without local fibrinolysis increased the overall mortality to over 65%. Conclusions: The study demonstrated the applicability of minimally invasive craniopuncture with local fibrinolysis for the management of supratentorial SICHs and the advantages it may have in certain categories of patients. The method proved particularly useful in lobar SICHs, being associated with the lowest mortality. Mixed SICHs do not represent a predilection for surgical interventions; however, the results related to mixed supratentorial locations need confirmation in larger cohorts.